Correction: Enhancing Endocannabinoid System in Residual MS Disease Without Relapses

Overview

This correction clarifies the funding sources for the study on improving the endocannabinoid system to address residual disease in relapse-free multiple sclerosis. The authors acknowledge financial support from Almirall S.p.A. for editorial assistance, which was not involved in the study design or analysis.

Background

Multiple sclerosis (MS) is a chronic neurological disorder characterized by relapses and residual disease progression. Enhancing the endocannabinoid system has been proposed as a therapeutic strategy to manage residual symptoms in relapse-free MS patients. Accurate disclosure of funding sources is critical for transparency in clinical research publications.

Data Highlights

No numerical data are presented in this correction notice.

Key Findings

• The original article incorrectly stated no financial support was received.
• The corrected statement acknowledges funding from Almirall S.p.A. for editorial assistance.
• The funding source had no role in study design, data collection, analysis, interpretation, or manuscript decisions.
• The correction ensures transparency regarding the collaboration with Protagon healthcare communication agency.
• The original article has been updated to reflect this correction.

Clinical Implications

Clinicians should be aware that the study on endocannabinoid system enhancement in MS was supported by external funding, although the funder did not influence the scientific content. Transparency in funding disclosures helps maintain trust in clinical research findings.

Conclusion

This correction updates the funding disclosure to accurately reflect financial support, reinforcing the integrity and transparency of the research on endocannabinoid system modulation in multiple sclerosis.

References

1. Annovazzi et al. 2026 -- Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis